Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15767908 | 0.88 | KMT2A (0.50) | HTTKMT2AMEN1ATML3MBTL1 | |
| SCHEMBL27867259 | 0.83 | KMT2A (0.56) | HTTKMT2AMEN1ATML3MBTL1 | |
| SCHEMBL5143899 | 0.82 | NPC1 (0.63) | HTTKMT2AMEN1ATML3MBTL1 | |
| SCHEMBL3142475 | 0.82 | S1PR4 (0.63) | HTTKMT2AMEN1ATML3MBTL1 | |
| SCHEMBL8159969 | 0.81 | KMT2A (0.54) | HTTKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL8789338 | 0.81 | KMT2A (0.54) | HTTKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL31040108 | 0.81 | HTT (0.53) | HTTKMT2AMEN1ATML3MBTL1 | |
| SCHEMBL26481653 | 0.81 | NPC1 (0.51) | HTTKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL17066377 | 0.80 | S1PR4 (0.60) | HTTKMT2AMEN1ATML3MBTL1 | |
| SCHEMBL4555887 | 0.79 | NPC1 (0.59) | HTTKMT2AMEN1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116589399-A | Preparation method of 3-methoxy-2-nitropyridine | 济南大学 | 2023-08-15 | — | — | CN | claimed |
| CN-103483247-B | Preparation method of 2-bromo-3-methoxypyridine | BEIJING GREENCHEM TECHNOLOGY CO LTD | 2015-05-13 | — | — | CN | claimed |
| CN-103483247-A | Preparation method of 2-bromo-3-methoxypyridine | BEIJING GREENCHEM TECHNOLOGY CO LTD | 2014-01-01 | — | — | CN | claimed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12528834-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2026-01-20 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-RE38073-E1 | Biosynthesis; using dehydration agent | RESEARCH CORPORATIONS TECHNOLOGIES, INC. | 2003-04-08 | — | — | US | disclosed |
| US-RE37686-E1 | Azahydroxybenzotriazoles and derivatives thereof for peptide coupling reactions | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-5698675-A | AMIDATION; ESTERIFICATION | RESEARCH CORPORATION TECH., INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5644029-A | TRIAZOLO-PYRIDINE HETEROCYCLIC COMPOUNDS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5580981-A | YELLOW INDICATORS FADING TO COLORLESS UPON COMPLETION OF THE ACYLATION STEP IN AMIDE FORMATION; REACTION ACCELERATORS; LOWERS RACEMIZATION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0662078-A1 | NEW REAGENTS FOR PEPTIDE COUPLINGS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994007910-A1 | NEW REAGENTS FOR PEPTIDE COUPLINGS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| US-4264599-A | HYPOTENSIVE AGENTS, ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-04-28 | — | — | US | disclosed |
| EP-0000485-A1 | Piperidino-propanols, their preparation and pharmaceutical compounds containing them | CIBA-GEIGY AG (CH) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | HTT 4049/4885KMT2A 1756/4885MEN1 4192/4885 |
| US-12528834-B2 | Method for producing peptide compound | VIP, IAPP, NPPA | HTT 162/4885KMT2A 3946/4885MEN1 355/4885 |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HTT 135/4885KMT2A 2161/4885MEN1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.